Locally Advanced Rectal Cancer Clinical Trial
Official title:
A Multicenter Phase II Trial of Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
Verified date | July 2013 |
Source | Zhejiang Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) is now considered as a standard treatment of locally advanced rectal adenocarcinomas, which correlates better local control and higher sphincter preservation rate. Nimotuzumab, a humanized monoclonal antibody against epidermal growth factor receptor (EGFR) has been reported to improve the therapeutic effect of radiotherapy in some cancers. This study is a clinical phase II trial designed to evaluate the efficacy of the combination of Nimotuzumab administered concurrently with neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer, and to further investigate its side-effect and toxicity.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | |
Est. primary completion date | April 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Written informed consent 2. Age:18-75 years 3. Histologically confirmed locally advanced colorectal cancer (adenocarcinoma) 4. The lower edge of the tumors located below 12 cm from the anal verge 5. Karnofsky Performance Scale =70 points, Life expectancy = 6 months 6. No prior chemotherapy was used 7. No history of regional radiation treatment inthe pelvic cavity 8. Adequate hematologic function: Hb = 100 g/L , WBC=3.5×109, ANC = 1.5×109 /L,PLT = 100×109 /L Adequate renal function: Cr = 1.5×ULN, TB=2.5 × ULN Adequate hepatic function: ALT/AST = 2.5×ULN, Alkaline phosphatase = 2.5×ULN 9. Patients without peripheral neuropathy Exclusion Criteria: 1. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ 2. Rectal cancer patients with concurrent colon cancer 3. Pregnant or lactating women 4. Fertile female patients without using any contraceptives 5. Allergic to cisplatin and fluorouracil 6. Patients with previous peripheral neuropathy 7. Serious complications: myocardial infarction, heart failure (NYHA Classification>II grade),psychiatric history and severe diabetes 8. Treatment with other anti-cancer therapy(including Chinese herbal medicine) 9. Organ transplant patients |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Zhejiang Cancer Hospital | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathology complete remission rate | Pathology complete remission rate is the primary outcome measure. | 1 year | No |
Secondary | tumor regression rate | 1 year | No | |
Secondary | local recurrence rate | 5 years | No | |
Secondary | overall survival | 5 years | No | |
Secondary | sphincter preservation rate | 3 years | No | |
Secondary | Incidence of Adverse Events | up to 1 month after the last cycle | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05079438 -
Dendrobium Huoshanense Suppository in Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT02964468 -
Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer
|
N/A | |
Not yet recruiting |
NCT05507112 -
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05998122 -
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
|
Phase 2 | |
Completed |
NCT04324567 -
Inflammation After Laparoscopic Robot-assisted Surgery for Locally Advanced Rectal Cancer
|
||
Recruiting |
NCT05412082 -
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
|
Phase 1 | |
Recruiting |
NCT05980689 -
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT02605265 -
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
|
Phase 3 | |
Terminated |
NCT02151019 -
Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05086627 -
Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Recruiting |
NCT03824899 -
UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT05845268 -
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
|
Phase 2 | |
Completed |
NCT03392584 -
Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
|
||
Terminated |
NCT04177602 -
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT05646511 -
Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE)
|
Phase 3 | |
Terminated |
NCT02290574 -
Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial
|
N/A | |
Recruiting |
NCT03702985 -
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05877352 -
Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial
|
N/A | |
Not yet recruiting |
NCT06375434 -
Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer
|